No OS Benefit from Continuous as Compared with Fixed-Duration Maintenance Therapy with Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma By Ogkologos - August 13, 2026 117 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENDURANCE study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma Chemotherapy-Free Regimen of Targeted Agent and Immunotherapeutic Superior to Imatinib and Chemotherapy Among Adult Patients with Ph-positive ALL Meet the first recipient of the ESMO Artificial Intelligence Fellowship MOST POPULAR ctDNA Analysis is Feasible for Detection of Minimal Residual Disease After... July 2, 2021 New study supports extending cervical screening intervals for people who test... May 31, 2022 EMA Recommends Granting a Marketing Authorisation for Catumaxomab November 12, 2024 Stopping TKI Treatment Is Safe, Improves Quality of Life for Some... December 15, 2020 Load more HOT NEWS The Appraisal – Scientific disruption: what is it, and do we... She Faced Breast Cancer At 16 With Little Help From Doctors.... 24-Year-Old Diagnosed With Breast Cancer After Doctors Said Her Chest Was... New Device Could “Hear” Stiffening of Extracellular Matrix to Determine Where...
